key: cord-0814082-blzsn91q
authors: Lelie, P. N.; Reesink, H. W.; Lucas, C. J.
title: Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine
date: 2005-12-07
journal: J Med Virol
DOI: 10.1002/jmv.1890230313
sha: 42a10ae22dbb8bb6bfaf713d0740c7ceb59332ef
doc_id: 814082
cord_uid: blzsn91q

The efficacy of two heating cycles (90 sec at 103°C and 10 hr at 65°C) used during manufacture of a plasma‐derived hepatitis‐B vaccine was validated for the inactivation of 12 virus families. A period of 15 min warming up to 65°C had already completely inactivated representatives of nine virus families, ie, poxvirus (vaccinia), picornavirus (encephalomyocarditis virus), togavirus (sind bis virus), coronavirus (mouse hepatitis virus), orthomyxovirus (influenza virus), rhabdovirus (vesicular stomatitis virus), herpes virus (cytomegalovirus), lentivirus (human immunodeficiency virus), and retrovirus (murine leukemia virus). After prolonged heating at 65°C or heating for 90 sec at 103°C, parvovirus (canine parvovirus) and the phage phiX174 were also completely inactivated. Papovavirus represented by simian virus 40 (SV‐40) was the most heat‐resistant virus evaluated. The infectivity of SV‐40 was reduced by 10(4) Tissue Culture Infectious Doses (TCID(50)) per ml after 90 sec at 103°C, but a marginal residual activity (<5 TCID(50) per ml) was observed. Subsequent pasteurization for 10 h at 65°C did not further reduce the infectivity of SV‐40. This study shows that the two heat‐inactivation steps used during the production of this vaccine kill a wide variety of viruses that might be present in human blood.

A plasma-derived hepatitis-B vaccine [Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB)], inactivated by two heating cycles (90 sec at 103 "C followed by 10 hr at 65 "C), is highly efficacious [Coutinho et al, 1983; Desmyter et al, 1983; Wong et al, 19841 . The safety of this vaccine has been established in chimpanzees [Reerink-Brongers et al, 19821 , and a reduction of at least 10" chimpanzeeinfectious doses (CID,,) of HBV during manufacture of the vaccine has been observed [Lelie et al, 19871 . Since the introduction of this vaccine, over 20,000 human individuals have been immunized without important side effects.

The procedures used in the manufacture of another vaccine [Merck, Sharp and Dohme (MSD) ] are effective in the inactivation of HBV [Tabor et al, 19831 and eight other virus groups [Gerety and Tabor, 19831 . The urea treatment inactivates rhabdovirus, poxvirus, togavirus, herpes virus, coronavirus, reovirus, myxovirus, and picornavirus. The pepsin treatment kills six of these virus groups but does not completely inactivate picornavirus as represented by mengovirus or myxovirus as represented by Newcastle disease virus. The effect of formalin has been reported to be rather modest in the inactivation of the human immunodeficiency virus (HIV) [Spire et al, 1984al in contrast with the effect of heat in a liquid environment [Spire et al, 1984b; Martin et al, 1985; McDougal et al, 1985; Resnick et al, 19861 . Both formalin and heat inactivate agents of non-A/non-B hepatitis [Tabor and Gerety, 1980; Yoshizawa et al, 19821. In this report, we describe the efficacy of the two heating steps applied during manufacture of hepatitis-B vaccine CLB in the inactivation of 12 virus families.

90 sec at 103 O C . A human serum protein solution (ultracentrifugation resuspension) was prepared from plasma negative for HBsAg, anti-HBc and anti-HBs according to methods described for the purification of hepatitis-B vaccine [Lelie et al, 19871 . For the inactivation of canine parvovirus (CPV), phiX174, and simian virus 40 (SV-40), 1 to 5 ml of virus stock solution were added to 50 ml of this human serum solution containing 6 mg of protein per ml. This mixture was heated in a 100-ml closed bottle for 90 sec at 103 "C in an oil bath and then cooled in an ice bath. The solution was centrifuged for 1 hr at 48,OOOg and the clarified supernatant was sterile filtered. The temperature in the bottle was continuously monitored with a data-logging apparatus (Kaye Instruments). Samples taken from the unheated solution and after heat treatment were immediately frozen in an ethanol-CO, bath. 10 h at 65 "C. The above human protein solution was heated for 90 sec at 103 "C. The heated solution was clarified by centrifugation at 48,OOOg and was then sterile filtered. For the inactivation of vaccinia virus, sindbis virus, encephalomyocarditis virus (EMC), mouse hepatitis virus (MHV), influenza virus, vesicular stomatitis virus (VSV), cytomegalovirus (CMV), HIV, murine leukemia virus (MuLV), CPV, and phiX174, 1 to 5 ml of stock solution were dissolved in 50 ml of this protein solution, containing 1 mg of protein per ml. This mixture was heated at 65 "C in a water bath, whereas in a dummy bottle filled with the same protein solution the temperature was continuously monitored. During the 15-min warming up and in the 10-hr pasteurization at 65 "C thereafter, several samples were taken and immediately frozen in ethanol-CO,. In one virus-inactivation experiment, the solution of SV-40, heated for 90 sec at 103 "C, was used directly for subsequent pasteurization.

The infectivity titers of the sequential samples of the virus preparations before, during, and after heat inactivation were tested in 10-fold dilutions, in duplicate or quadruplicate. This was done by assessing the percentage of cell cultures at each dilution Table I summarizes the viruses that had already been inactivated within a period of 15 min that was required to reach a temperature of 65 "C. Although the infectivity titers of the various preparations before heating varied considerably, no residual activity was observed for nine virus families after the 15 min required to reach 65 "C. Table I1 shows the heat-resistant viruses that were inactivated only after heating at 103 "C or prolonged heating at 65 "C. The infectivity of CPV was reduced by 102.3 TCID,, per ml within 40 min at 65 "C and by at least los.' TCID,, per ml after both 10 hr at 65 "C and 90 sec at 103 "C. The infectivity of phiX174 was already reduced by lo5.' TCID,, per ml after 9 min of heating at 65 "C and no residual activity was observed after heating of lo7 TCID,, per ml for 10 hr at 65 "C or for 90 sec at 103 "C. A reduction of lo4 TCID,, per ml of SV-40 was found after 90 sec of heating at 103 "C of lo5.' TCID,, per ml. The marginal residual activity ( 5 lo'.' TCID,, per ml) remained unaltered after subsequent pasteurization for 10 hr at 65 "C. However, the protein concentration during the pasteurization of the residual infectivity of SV-40 was 6-fold higher than the usual protein concentration during pasteurization of the vaccine.

The experiments show that vaccinia virus, EMC, sindbis virus, MHV, influenza virus, VSV, CMV, HIV, and MuLV are evidently highly sensitive to heat treatment, because no viral infectivity was recovered after the 15 min required to reach the temperature of 65 "C. At least lo5 TCID,, per ml of CPV and lo7 TCID,, per ml of the phage phiX 174 were completely inactivated after prolonged pasteurization at 65 "C or after 90 sec heating at 103 OC. The infectivity of SV-40 was reduced by lo4 TCID,, per ml after 90 sec at 103 "C, but a marginal residual infectivity of ~l o ' .~ TCID,, per ml was not eliminated by subsequent pasteurization. Because in this experiment the protein concentration during pasteurization was higher than during regular production of the vaccine, the inactivation of the final heating step for SV-40 may be underestimated as a consequence of too high a concentration of protective proteins. Similar results were reported by Rohwer [1983] who found heat-resistant subpopulations of phage X at 60 "C, but only in the presence of brain homogenate.

Our study confirms results of other investigators who have also established that HIV is effectively killed in a liquid environment [Spire et al, 1984; Martin et al, 1985; McDougal et al, 1985; Resnick et al, 19861 . A representative of the group of slow viruses was not included in our study, but Rohwer [1983] has reported that 97% of the heat-resistant scrapie agent was destroyed within 2 min of exposure to 100 "C in aqueous solution.

The absence of extraneous infectious agents in the starting plasma of each lot of the vaccine is confirmed according to the requirements of the World Health Organization [1980] . Hence, it is highly unlikely that batches of the vaccine that have passed this test contain residual infective virus after the purification and inactivation steps used.

Efficacy of a heat-inactivated hepatitis-B vaccine in male homosexuals: Outcome of a placebo-controlled double-blind trial

Efficacy of heat-inactivated hepatitis-B vaccine in haemodialysis patients and staff: Double-blind, placebo-controlled trial

Newly licensed hepatitis-B vaccine: Known safety and unknown risks

Safety of a plasma-derived hepatitis-B vaccine inactivated by two heating cycles: 90 seconds at 103 OC and 10 hours pasteurization at 65 OC. I . Inactivation studies of HBV in chimpanzees

Disinfection and inactivation of the human T-lymphotropic virus type 111: Lymphadenopathy-associated virus

Inactivation of the acquired immunodeficiency syndrome virus, human T-lymphotropic virus I JI/lymphadenopathy-associated virus, with special reference to antihemophilic factor

Preparation and evaluation of heat-inactivated HBsAg as a vaccine against hepatitis B

Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments

Virus-like sensitivity of the scrapie agent to heat inactivation

984a): Inactivation of lymphadenopathyassociated virus by chemical disinfectants

Inactivation of lymphadenopathy-associated virus by heat, gamma rays and ultraviolet light

Inactivation of an agent of human non-A, non-B hepatitis by formalin

Inactivation of hepatitis-B virus by three methods: Treatment with pepsin, urea or formalin

Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin

World Health Organization (1 980): Proposed requirements for hepatitis-B vaccine. WHO Expert Committee on Biological Standardization

Nan-A, non-B (type 1) hepatitis agent capable of inducing tubular ultrastructures in the hepatocyte cytoplasma of chimpanzees: Inactivation by formalin and heat